Given our company's broad experience in the field of Acinetobacter infection research, we are ready to provide bespoke Acinetobacter infection therapy development assistance as well as comprehensive support in the research process for the research in question.
Introduction to Acinetobacter Infection
Infectious diseases find many challenges in Acinetobacter infections, especially in the hospital setting. The Acinetobacter species are gram negative rods that can survive on dry surfaces for many days. The most important of these is Acinetobacter baumannii which accounts for almost 80% of the acquired infections. Other common types of Acinetobacter infection include Respiratory tract infections, wound infections and urinary tract infections.
Fig. 1 The mechanism of infection with Acinetobacter baumannii in respiratory diseases. (Yao Y, et al., 2023)
Pathogenesis of Acinetobacter Infection
The pathogenesis and colonizing ability of Acinetobacter is dependent on many factors that influence their persistence and virulence.
Colonization
Acinetobacter species are capable of infecting the skin of not only healthcare personnel but also patients, thus serving as a source of infection. Moreover, the propensity of Acinetobacter to stick to surfaces and form biofilms adds to its range of adaptability in medical institutions.
Virulence Factors
As a matter of fact, all Acinetobacter species have developed several virulence factors such as capsular polysaccharides, outer membrane proteins such as OmpA and CarO, efficiencies in iron acquisition, and efflux pumps which enable them successfully instigated infections and escaped various immune responses.
Immune Evasion
Acinetobacter has devised tactics to avoid host immune responses, facilitating its colonization and infection of hosts. These bacteria are able to alter host immune signalling mechanisms, disturb the production of cytokines and also obstruct immune cell phagocytosis and killing.
Vaccine Development for Acinetobacter Infection
Developing vaccines against Acinetobacter is significantly hampered due to its complex outer membrane and the ability to gain drug resistance. So far, we still have no vaccines on the market but substantial strides have been made in preclinical and early research.
Targeting Surface Proteins
A range of surface proteins, OmpA, OmpW and CarO, have been discovered and studied and are now reported to be of significance in the pathogenesis of Acinetobacter infections. There have been studies which employed these proteins as vaccine antigens and have showed encouraging results in preclinical models.
Outer Membrane Vesicles (OMVs)
OMVs obtained from Acinetobacter have demonstrated promise as vaccine candidates, as these OMVs can induce a robust immune response. Such OMVs also provide protection by boosting the immune system and decreasing bacterial transmission as demonstrated in preclinical studies.
Therapy Development of Acinetobacter Infection
In hospitals, Acinetobacter infections are a considerable concern as they are on the rise and multi-drug resistant As a countermeasure, researchers are working on the discovery of new treatment methods which focus on different characteristics of the Acinetobacter infection. Developing Acinetobacter infection therapies which are expected to be able to treat infections at various stages include the following:
| Therapies |
Drug Types |
Mechanism of Action |
Research Phase |
| Plazomicin |
Aminoglycoside antibiotic |
Inhibit bacterial protein synthesis |
Phase III clinical trials |
| Cefiderocol |
Siderophore cephalosporin antibiotic |
Inhibit cell wall synthesis |
Phase III clinical trials |
| Eravacycline |
Fluorocycline antibiotic |
Inhibit bacterial protein synthesis |
Phase III clinical trials |
| Antimicrobial Peptides (AMPs) |
Peptides |
Disrupt bacterial cell membranes, inhibit protein or nucleic acid synthesis |
Preclinical research |
Our Services
As we are fully engaged in the research of infectious diseases for many years, our company possesses highly qualified personnel and a vast amount of experience. We employ advanced technologies in the development of novel diagnostic kits that strive towards the early diagnosis of Acinetobacter infection. We create animal models and carry out detailed studies of the etiology and targets of Acinetobacter infection to further develop therapeutic drugs.
Therapeutic Development Services
By Molecule Types
Vaccine Development Services
In order to prevent Acinetobacter infection, our organization focuses on vaccine development for Acinetobacter infection prevention. We recognize the problems posed by the complicated outer membrane, and antibiotic resistance of Acinetobacter, and we employ the newest technologies as well as creative methodologies to surmount these challenges. We are also able to create a wide variety of vaccine types, including but not limited to the following:
Animal Models Development of Acinetobacter Infection
We make use of a variety of species, like mice, rats, galleria mellonella, non-human primates and others, to build transgenic animal models for Acinetobacter infection.
Pathogen Infection Models
For our experiments, Acinetobacter infection is produced in animal models by the nasal route or by intraperitoneal of the bacteria or through the intravenous route. By controlling the inoculum of the bacteria and the immunological status of the animal, the severity and spread of the infection can be regulated appropriately.
Genetically Engineering Models
We can construct transgenic models, conditional knockout models, overexpression models, and other types of genetic engineering models. Such modifications enable us to delve into the nitty gritty of infection processes, how the host interacts with the pathogen, and even the evolution of new treatment strategies through the use of molecular mechanisms.
Humanized Models
The potential effectiveness of antibiotics or immune therapy for treating Acinetobacter infections has been studied utilizing humanized models, these models more closely reflect human immune responses, and it is possible to test therapeutic approaches in a preclinical context.
With complete animal species resources, we can meet your diversified preclinical research needs, including drug safety evaluation, pharmacodynamics and pharmacokinetic analysis. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Yao Y, Chen Q, Zhou H. Virulence Factors and Pathogenicity Mechanisms of Acinetobacter baumannii in Respiratory Infectious Diseases[J]. Antibiotics, 2023, 12(12): 1749.
- Almasaudi S B. Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features[J]. Saudi journal of biological sciences, 2018, 25(3): 586-596.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
